Clinical Trial Update: Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicates danicopan as an add-on to ravulizumab or eculizumab in pediatric patients with paroxysmal nocturnal hemoglobinuria and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)
• Eculizumab (eculizumab)
• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Status: RECRUITING